Shots:

• Y-Trap to receive up front- pre/clinical development- regulatory & commercial milestones with royalties on sales. Merck KGaA & Y-Trap will explore pharmacology of Y-Trap multifunctional proteins while Merck will be responsible for development- manufacturing and commercialization activities
• The collaboration involves Y-Trap's platform of multifunctional antibody-ligand traps for immuno-oncology and Merck KGaA’s expertise in the research and development of bi-functional antibodies and proteins
• The Y-Trap platform exploits combinatorial protein engineering countering key determinants of immune dysfunction in the tumor microenvironment. The antibody-ligand traps have an ability to unleash potent antitumor immune responses offering an immunotherapeutic strategy for advanced/refractory cancer indications

Click here to­ read the full press release/ article 

Ref: PRNewswire | Image: Merck KGaA